Abstract
The identification and validation of biomarkers for preclinical patients with mild cognitive impairment (MCI) at-risk for Alzheimer’s disease (AD) development is increasingly important. We used the cytofluorimetric analysis of unfolded p53 to determine the prognostic ability of the protein as predictive signature from MCI to AD in a longitudinal study of a population of presymptomatic patients with the clinical diagnosis of MCI.
Venous blood samples from 24 healthy subjects, 28 MCI and 15 AD were analyzed with the cytofluorimetric method for unfolded p53 protein detection. Twenty-four MCI patients had clinical follow-up subsequent to the analysis for unfolded p53. Elevated levels of the conformationally altered protein were able to discriminate both MCI and AD patients comparing with healthy subjects. Longitudinal follow-up revealed that 7/24 MCI patients progressed to AD. All converters (100%) were predicted by elevated levels of unfolded p53, with a positive predictive value of 87.5%.
These data support and extend our previous observation that the cytofluorimetric approach for unfolded p53 protein was able to discriminate AD patients from healthy subjects and to predict the progression from MCI to AD in presymptomatic patients before clinical diagnosis for AD was evident.
Keywords: Alzheimer’s disease (AD), blood biomarker, flow cytometry, mild cognitive impairment (MCI), unfolded p53, positive predictive value, Molecular Genetic, neuropsychological battery
Current Alzheimer Research
Title:Searching for Predictive Blood Biomarkers: Misfolded p53 In Mild Cognitive Impairment
Volume: 9 Issue: 10
Author(s): Serena Stanga, Cristina Lanni, Elena Sinforiani, Giuliano Mazzini and Marco Racchi
Affiliation:
Keywords: Alzheimer’s disease (AD), blood biomarker, flow cytometry, mild cognitive impairment (MCI), unfolded p53, positive predictive value, Molecular Genetic, neuropsychological battery
Abstract: The identification and validation of biomarkers for preclinical patients with mild cognitive impairment (MCI) at-risk for Alzheimer’s disease (AD) development is increasingly important. We used the cytofluorimetric analysis of unfolded p53 to determine the prognostic ability of the protein as predictive signature from MCI to AD in a longitudinal study of a population of presymptomatic patients with the clinical diagnosis of MCI.
Venous blood samples from 24 healthy subjects, 28 MCI and 15 AD were analyzed with the cytofluorimetric method for unfolded p53 protein detection. Twenty-four MCI patients had clinical follow-up subsequent to the analysis for unfolded p53. Elevated levels of the conformationally altered protein were able to discriminate both MCI and AD patients comparing with healthy subjects. Longitudinal follow-up revealed that 7/24 MCI patients progressed to AD. All converters (100%) were predicted by elevated levels of unfolded p53, with a positive predictive value of 87.5%.
These data support and extend our previous observation that the cytofluorimetric approach for unfolded p53 protein was able to discriminate AD patients from healthy subjects and to predict the progression from MCI to AD in presymptomatic patients before clinical diagnosis for AD was evident.
Export Options
About this article
Cite this article as:
Stanga Serena, Lanni Cristina, Sinforiani Elena, Mazzini Giuliano and Racchi Marco, Searching for Predictive Blood Biomarkers: Misfolded p53 In Mild Cognitive Impairment, Current Alzheimer Research 2012; 9 (10) . https://dx.doi.org/10.2174/156720512804142886
DOI https://dx.doi.org/10.2174/156720512804142886 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents Melatonin and Its Therapeutic Potential in Neuroprotection
Central Nervous System Agents in Medicinal Chemistry Role and Therapeutic Potential of Astrocytes in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design The Role of Iron Toxicity in Oxidative Stress-induced Cellular Degeneration in Down Syndrome: Protective Effects of Phenolic Antioxidants
Current Nutrition & Food Science The Glutathione System and its Regulation by Neurohormone Melatonin in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Vitamin E and All-Cause Mortality: A Meta-Analysis
Current Aging Science A Comprehensive Review on Recent advances in Synthesis & Pharmacotherapeutic potential of Benzothiazoles
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds Importance of Zebrafish as an Efficient Research Model for the Screening of Novel Therapeutics in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Organotypic Cultures as Tool to Test Long-Term Effects of Chemicals on the Nervous System
Current Medicinal Chemistry Curcumin Exposure Modulates Multiple Pro-Apoptotic and Anti-Apoptotic Signaling Pathways to Antagonize Acetaminophen-Induced Toxicity
Current Neurovascular Research Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research Securinine Derivatives as Potential Anti-amyloid Therapeutic Approach
CNS & Neurological Disorders - Drug Targets Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Current Medicinal Chemistry Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design